PrevenTRON has reached a UK NHS recruitment site, with Surrey and Borders Partnership NHS Foundation Trust leading UK enrolment. The international Phase III study will test whether investigational trontinemab can delay or prevent symptomatic Alzheimer's disease before symptoms begin. The research is important, but it does not show that Alzheimer's can already be prevented. It is designed to find out whether an experimental treatment is effective and safe in people who have no symptoms.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What is PrevenTRON testing?
- Who may be able to participate?
- Why study treatment before symptoms appear?
- What are the limits of the announcement?
What is PrevenTRON testing?
PrevenTRON is a Roche-sponsored, placebo-controlled study involving about 1,600 participants worldwide. The UK NHS site is therefore one part of a global trial, not a separate NHS-only project. Trontinemab is an investigational antibody that targets amyloid-beta.
Roche says the study will use a pTau217 blood test to help identify cognitively unimpaired people at high risk of progression in its PrevenTRON programme. Participants have biological markers associated with Alzheimer's pathology but no cognitive or functional impairment. Researchers will investigate whether treatment can delay progression to mild cognitive impairment or Alzheimer's dementia.
Who may be able to participate?
Surrey and Borders Partnership NHS Foundation Trust says it is recruiting healthy adults aged 55 to 80 from anywhere in the UK, subject to screening. Applicants should have no Alzheimer's symptoms or memory problems, according to the Trust's PrevenTRON recruitment page.
The basic checks are: Meeting those points does not guarantee enrolment. Screening must also establish whether a potential participant fits the study's biomarker-based target group.
- Age 55 to 80
- No Alzheimer's symptoms
- No memory problems
- Willingness to undergo study screening
Why study treatment before symptoms appear?
PrevenTRON focuses on an earlier stage than most people associate with Alzheimer's disease. Participants function normally but have biomarkers—measurable biological signs—that indicate Alzheimer's pathology and a risk of future decline. This design asks whether intervening before memory or daily function deteriorates can change what happens next.
The ClinicalTrials.gov study record describes participants as being at risk of progressing to mild cognitive impairment or Alzheimer's dementia. That distinction matters for families. PrevenTRON is not a treatment programme for someone already experiencing Alzheimer's symptoms, and absence of symptoms alone does not establish eligibility.
What are the limits of the announcement?
Trontinemab remains investigational. Because PrevenTRON is an efficacy-and-safety trial comparing treatment with placebo, its results are needed before anyone can say whether the medicine delays or prevents symptomatic disease. Public status information also contains a timing discrepancy.
The NHS Trust's page presents the site as recruiting, while the ClinicalTrials.gov record posted on 21 July 2026 listed the study as "not yet recruiting." The available information does not explain the difference, so prospective participants should use the NHS recruitment page for the site's stated position. The wider advice has not changed: the NHS says there is currently no certain way to prevent Alzheimer's disease. Anyone considering PrevenTRON should treat it as research with uncertain benefits, not as proven preventive care.
